ImmunoGen Message Board - Msg: 14756651

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Boris Maleshev who wrote (3683)	11/8/2000 2:05:55 PM
From: Carson O. Ray, Jr.	Read Replies (1) of 5665

C242 Summary at aacr.edoc.com From presentations Index at Proceedings of the 11th NCI·EORTC·AACR Symposium on New Drugs in Cancer Therapy web site (list at aacr.edoc.com Bottom Line: Preliminary pharmacokinetic data (ELISA) at the 88 mg/m2 dose level demonstrated a mean (±SD) peak plasma concentration 99.3 ± 29.9 µg/mL and a prolonged elimination half-life averaging 44 hours. No evidence of human anti-human antibody formation has been detected and dose escalation continues. One patient (88 mg/m2) with pancreatic carcinoma has had stable disease over 5 courses of therapy. So far, SB-408075 can be safely administered IV once every 21 days at doses consistent with impressive activity in preclinical models.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next